Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2017
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Enanta Pharmaceuticals (ENTA) PT Raised to $82 at Baird
February 8, 2018 6:43 AM ESTBaird raised its price target on Enanta Pharmaceuticals (NASDAQ: ENTA) to $82.00 (from $46.00) while maintaining a Neutral rating on strong Hep C royalties/pipeline progress.
... MoreEnanta Pharma (ENTA) Tops Q1 EPS by 40c
February 7, 2018 4:02 PM ESTEnanta Pharma (NASDAQ: ENTA) reported Q1 EPS of $0.59, $0.40 better than the analyst estimate of $0.19. Revenue for the quarter came in at $38.1 million versus the consensus estimate of $31.15 million.
Net income for the three months ended December 31, 2017 reflects the $3.8 million, or $0.19 per... More
